Group 1 - CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders, specifically presenting at the upcoming AP/PD™ conference [1][2][3] - The company will present detailed analyses from the Extension Phase of the RewinD-LB Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB) [1][2] - Neflamapimod is an investigational orally administered small molecule that inhibits p38 mitogen-activated protein kinase alpha, with potential applications in treating synaptic dysfunction associated with neurodegenerative processes [3] Group 2 - The oral presentation will take place on April 5th, 2025, from 18:25 to 18:40 CET, featuring key figures from CervoMed and Harvard Medical School [2] - The abstract of the presentation will be made available in the Investor section of CervoMed's website following the event [2]
CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™)